Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Stopped early · Phase 2
Conditions studied: NSCLC
In brief
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven participant cohorts for up to 603 previously treated and treatment-naïve NSCLC participant. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7).
Key facts
- Study ID
- NCT03318939
- Run by
- Spectrum Pharmaceuticals, Inc
- People needed
- 648
- Starts
- 2017-10-11
- Expected to finish
- 2023-04-03
- Last updated by the study team
- 2026-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Oncology Physician's Network Inc./OPN Healthcare — Arcadia, California, United States
- City of Hope — Duarte, California, United States
- UCSD -Moores Cancer Center — La Jolla, California, United States
- Pacific Shores Medical Group — Long Beach, California, United States
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California, United States
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- UC Davis Comprehensive Cancer Center — Sacramento, California, United States
- UCSF Helen Diller Comprehensive Cancer Center at Mt Zion — San Francisco, California, United States
- UCLA Hematology/Oncology — Santa Monica, California, United States
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California, United States
- Kaiser Permanente Medical Center — Vallejo, California, United States
- Rocky Mountain Cancer Center — Boulder, Colorado, United States
- Yale University, Yale Cancer Center Smilow Cancer Hospital at Yale — New Haven, Connecticut, United States
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- Florida Hospital — Orlando, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
- The Bond & Steele Clinic, P.A. dba Bond Clinic, P.A. — Winter Haven, Florida, United States
- University Cancer & Blood Center, LLC — Athens, Georgia, United States
- CTCA - Southeastern Regional Medical Center — Newnan, Georgia, United States
- CTCA - Midwestern Regional Medical Center — Zion, Illinois, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota, United States
- Mayo Clinic Hospital — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.